[A Case of Anaplastic Carcinoma of the Pancreas with Long-Term Prognosis by Multidisciplinary Treatment]

A 67-year-old man presented with obstructive jaundice in March 2022 and was diagnosed with borderline resectable pancreatic head cancer. Gemcitabine+nab-paclitaxel(GnP)was started as preoperative chemotherapy, and tumor shrinkage was observed. In August of the same year, he underwent a subtotal stomach-preserving pancreaticoduodenectomy, combined portal vein resection and reconstruction. The pathological evaluation of surgical specimen demonstrated that it was anaplastic pancreatic cancer and he was treated with adjuvant chemotherapy with GnP. In April 2023, a CT scan confirmed that there was no recurrence or metastasis, and the patient was given 20 doses of anticancer drugs over a 6 months period and then stopped taking them. In August of the same year, the chemotherapy was resumed due to the finding of elevated CA19-9. Immediately after the administration, a decrease in CA19-9 was observed, however it rose again in February 2024, and a CT scan indicated tumor recurrence in the residual pancreas. He is currently being followed up on an outpatient basis with S-1 medication. Anaplastic carcinoma has a poor prognosis, but we have experienced a case of long-term survival of approximately 2 years after surgery with multidisciplinary treatment.